A Study of TY-1091 in Patients With Advanced Solid Tumors
NCT05675605
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
248
Enrollment
INDUSTRY
Sponsor class
Conditions
RET-altered Non Small Cell Lung Cancer
Medullary Thyroid Cancer
RET-altered Papillary Thyroid Cancer
Neoplasms
Interventions
DRUG:
TY-1091
Sponsor
TYK Medicines, Inc